Loretta J. Nastoupil, MD

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss future research to watch in follicular lymphoma.

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss the role of targeted therapies and rechallenging with certain classes of agents in follicular lymphoma.

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss factors that can inform sequencing planning in follicular lymphoma management.

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss data for tafasitamab- and epcoritamab-based combinations in relapsed/refractory follicular lymphoma.

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss methods of building on the lenalidomide/rituximab backbone in relpased/refractory follicular lymphoma.

Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss treatment selection in relapsed/refractory follicular lymphoma.

Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.

Loretta J. Nastoupil, MD, discusses the rationale for investigating the use of lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.

A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.

Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.

Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.

Marc S. Hoffman, MD, provides an overview of recent updates in the treatment of relapsed/refractory diffuse large B-cell lymphoma.